Xlife Sciences AG Ordinary Shares XLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CHF 32.00
- Day Range
- CHF 32.00–33.80
- 52-Week Range
- CHF 31.50–51.40
- Bid/Ask
- CHF 31.20 / CHF 33.90
- Market Cap
- CHF 191.06 Mil
- Volume/Avg
- 3,755 / 9,446
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 245.51
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Xlife Sciences AG is a Swiss company with a focus on performance technologies in life sciences. The company allows its investors a very early and direct Entry into the further development of innovative and future-oriented technologies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 17
- Website
- https://www.xlifesciences.ch
Comparables
Valuation
|
Metric
|
XLS
|
INA
|
KOMN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 22.14 | 20.17 |
Price/Book Value | 0.70 | 0.81 | 2.11 |
Price/Sales | 245.51 | 11.92 | 1.09 |
Price/Cash Flow | 50.64 | — | 14.33 |
Price/Earnings
XLS
INA
KOMN
Financial Strength
|
Metric
|
XLS
|
INA
|
KOMN
|
|---|---|---|---|
Quick Ratio | 3.11 | 0.05 | 1.71 |
Current Ratio | 3.11 | 0.16 | 3.11 |
Interest Coverage | 12.70 | −1.35 | 12.75 |
Quick Ratio
XLS
INA
KOMN
Profitability
|
Metric
|
XLS
|
INA
|
KOMN
|
|---|---|---|---|
Return on Assets (Normalized) | −7.80% | −1.30% | 5.48% |
Return on Equity (Normalized) | −15.67% | −4.95% | 10.15% |
Return on Invested Capital (Normalized) | −9.47% | −0.85% | 7.66% |
Return on Assets
XLS
INA
KOMN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vwzjgjbc | Ntht | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rdqnjwt | Lqzkny | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bkgrqmyn | Kgsytwy | $103.7 Bil | |
MRNA
| Moderna Inc | Rcctjmjp | Fjdlw | $47.9 Bil | |
ARGX
| argenx SE ADR | Tzqffbjbp | Cydn | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Kbnxktwn | Slmq | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Prdbtdsnd | Rcwdlc | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sxkpsywff | Sdnlmv | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cpvgsxtbgr | Hfmkxd | $12.8 Bil | |
INCY
| Incyte Corp | Msqctczk | Vzzgbmk | $12.1 Bil |